Walter Piskorski

C. R. Bard, Inc. engages in designing, development, manufacturing, packaging, distribution, and sales of medical, surgical, diagnostic, and patient care devices. It sells its products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. The company was founded by Charles Russell Bard in 1907 and is headquartered in Franklin Lakes, NJ.

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.

Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA.

Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA.

Part of Amphastar Pharmaceuticals, Inc., Armstrong Pharmaceuticals, Inc. is a private company that manufactures aerosol pharmaceutical products. The company is based in New Canaan, CT.

Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA.